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Abstract
Background: Few empirical data show the pattern of functional decline at the end of life for
cancer patients, especially among older patients.
Methods: In a mortality follow-back survey (the Italian Survey of the Dying of Cancer – ISDOC)
a random sample of 1,271 lay caregivers were interviewed, at a mean of 234 days after
bereavement. The main outcome was number of days before death when the patient experienced
a permanent functional decline.
Results: 1,249 (98%) caregivers answered the question about patient's function. The probability
to be free from a functional disability was high (94%) 52 weeks before death, but was lower for
older age groups (15% for those aged 85 or more) and women (8%). It remained stable until 18
weeks before death, then fell to 63% at 12 weeks and 49% at 6 weeks before death (among those
aged 85 or more the figures were 50% and 41%). The pattern was consistent across sub-groups,
except for patients affected by Central Nervous System tumors who experienced a longer, slower
functional decline.
Conclusion: This study provides empirical support for the declining trajectory in cancer, and
suggests that the decline commences at around 12 weeks in all age groups, even among patients
over 85 years.
Background
Although functional status is a well know prognostic indi-
cator in cancer [1-3], the pattern of decline is less well
understood. In 2003, Lunney et al. proposed a model of
theoretical patterns of functional decline at the end of life,
showing four main trajectories, sudden death, terminal
illness, organ failure and frailty [4]. The authors analysis,
and a previous study [5], suggested most people dying
from cancer fell into the category of 'terminal illness',
which showed high function early in their final year, but
marked more disability three months prior to death.
These results, derived from cross-sectional studies, have
not yet been re-tested in other research with different
designs. The trajectories are now being used to underpin
government strategies in many countries to help deter-
mine eligibility for hospice and palliative care services.
Following USA trends, European Clinicians are being
encouraged to use changing function and time (such as in
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the UK End of Life Strategy) to decide when to refer
patients to hospice and palliative care services. However,
because of demographic changes and improvements in
treatment, cancer patients increasingly are older [6,7].
Most of the studies examining the role of functional status
in prognosis have excluded older people, with the
assumption that disability due to co-morbidity will lead
to misclassification [3]. Therefore, in this study we aimed
to provide empirical data to test the hypothesis of a trajec-
tory of stable disease followed by rapid decline in cancer
at the end of life. We wished to test whether the trajecto-
ries were universal, or were they different among patients
with different ages, gender and primary cancer diagnosis.
Methods
A 2-stage probability sample was used to estimate end-of-
life outcomes of approximately 160,000 annual cancer
deaths in Italy. In the 1st sampling stage, 30 out of 197
existing Local Health Districts (LHD) were randomly
selected. In the 2nd stage, a fixed proportion of cancer
deaths aged 18 years or more were randomly drawn from
each LHD, providing a sample of 2,000 death certificates
for people who died from cancer between March 2002
and June 2003. For each case included in the survey, the
non-professional caregiver, who was defined as the closest
and the best informed person about the patient's last three
months of life, was identified. A professional caregiver
was identified for 57 deceased (3%) who were alone and
without any non-professional support. A letter was sent to
all identified caregivers to inform them of the study aims
and obtain formal consent to be interviewed. A trained
interviewer contacted the identified caregiver to discuss
the interview in detail. Information regarding the meth-
odology of the survey has been published in a previous
article [8].
The interviewer met the caregiver, usually in his/her
home, to conduct a semi-structured interview using an
adapted version of the VOICES questionnaire [9]. A spe-
cific section of the interview dealt with the major func-
tional decline of the patient. More specifically, the
caregiver was asked:
• When did the patient start to need assistance or help to
wash, dress, eat or walk around the house?" (Days before
death).
During specific training settings, the interviewers were
instructed to specify the caregiver that the question
referred to any cause of disability, not only cancer.
The study design was approved by the Ethical Committee
of National Cancer Institute of Genoa, and, according to
the Italian law on use and processing of health data, a
notification of the study design and procedures was sent
to the Italian Data Protection Commission.
Statistics
The probability to be free from a major and permanent
functional disability has been modelled in the 52 weeks
before death using life-table statistical analysis. The last
year of life was subdivided in 26 intervals of two weeks.
The cumulative probability to be free from functional dis-
ability was estimated at the end of each interval and for
each point the standard error calculated.
All analyses were performed using SUDAAN version 9.0.1
(Research triangle Institute, Research Triangle Park, NC).
This software, for the point and standard error statistic
estimation, takes into account the unequal probability
selection of observations, stratification and clustering of
observations. Sampling weights were introduced to
obtain unbiased weighted point estimates and standard
error of the target population. Chi-square test for hetero-
geneity was used to examine the distribution of caregiver
relationship by the characteristics of the study sample.
Results
An interview was conducted with 1,289 (67.8%) of the
1,900 identified caregivers at an average of 234 days after
the patients' death (range 103–374). Six patients whose
cause of death was not cancer and twelve without a termi-
nal phase of disease were excluded from all the statistical
analysis, leaving a total sample of 1,271 valid interviews,
and of these 1,249 (98.3%) caregivers answered the ques-
tion about patient's function.
Responding caregivers were a child (46.4%), the spouse
(30.3%), another family member or a friend (20.4%), or
a health professional for patients with no lay caregiver
(2.9%). Most cancer patients were at least 65 years old at
death (80.8%) and 57.4% were men. About two-third
(67%) completed only primary schools. Tumors from the
digestive, respiratory or genitourinary system accounted
for 72% of all cancer deaths. (Table 1). There was a signif-
icant relationship between responding caregiver and age,
gender, level of patient education and primary tumor
(Table 1). Spouse respondents more commonly reported
about patients who were younger, men, with the highest
education level and suffering from respiratory primary
tumors. Conversely, children more frequently reported
about patients who were older, women, with the lowest
educational level. Similarly, for patients without caregiv-
ers, health professionals more frequently reported about
those who were older, women, with the lowest educa-
tional level.
For all cancer patients, the probability to be free from a
major and permanent functional disability was very highBMC Cancer 2008, 8:127 http://www.biomedcentral.com/1471-2407/8/127
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(94%) 52 weeks before death. It decreased slightly during
the next 34 weeks (Figure 1 and Table 2). Most patients
became functionally disabled during the last 18 weeks of
life. Their probability to be free from disability decreased
from 88% (18 weeks before death) to 63% (12 weeks
before death), to 49% (6 weeks before death), to 23% (2
weeks before death).
When we examined the probability to be free from func-
tional disability in the year before death, by gender, age
and primary tumors (Table 2), two phenomena emerged.
First, the patterns in all subgroups were similar, showing
a period of stable, higher function followed by rapid
decline starting at 12–18 weeks before death. The only
remarkable exception is the group of patients affected by
Central Nervous System (CNS) tumors who experienced a
longer, slower functional decline starting 24 weeks before
death. Second, a higher proportion of disabled cancer
patients 52 weeks before death was observed for older age
groups (15% for those aged 85 or more) and for women
(8%). These differences between sub-groups remained
throughout the trajectory until the last 2 weeks before
death.
Figure 1 shows the probability to be free from functional
disability in the 52 weeks before death in men and
women by age group. The patterns of functional decline
were comparable for all six subgroups and older age
groups show a higher proportion of disabled cancer
patients one year before death both among males and
females.
Table 1: Characteristics of the study sample by caregiver relationship
TOTAL Spouse Daughter – Son Other Relatives Health Professionals
N. % N. % N. % N. % N. %
AGE AT DEATH (years)
18–64 242 19.2 128 32.5 56 10.2 56 20.9 2 4.6
65–84 785 64.1 237 64.1 391 68.6 139 54.9 18 51.2
85 + 222 16.7 14 3.3 132 21.1 60 24.2 16 44.2 P < 0.001
GENDER
Males 700 57.4 297 79.9 281 49.3 109 43.7 13 34.1
Females 549 42.6 82 20.1 298 50.7 146 56.3 23 65.9 P < 0.001
EDUCATION (years)
≤ 5 819 66.9 203 54.2 427 75.2 163 66.7 26 72.1
6–8 224 17.1 86 21.8 86 14.0 45 16.6 7 19.8
≥ 9 205 16.0 90 24.0 65 10.8 47 16.7 3 8.1 P < 0.001
PRIMARY TUMOR
Digestive 453 35.6 120 30.4 237 39.7 87 35.2 9 25.9
Respiratory 262 21.7 113 29.3 99 18.4 44 18.4 6 16.3
Breast 124 10.0 29 7.8 52 9.1 30 11.7 13 40.3
Genitourinary 184 14.8 58 16.3 85 14.5 38 13.9 3 6.8
Haematological 91 7.5 26 7.0 45 8.2 17 6.7 3 6.8
Nervous Central System 32 2.7 9 2.8 15 2.8 8 2.7 - -
Others 103 7.8 24 6.5 46 7.4 31 11.4 2 3.9 P = 0.003
TOTAL 1,249 100 379 100 579 100 255 100 36 100
NOTE: all percentages are weighted column percentages
Probability to be free from functional disability in the year  before death of cancer patients in men and women by age  group Figure 1
Probability to be free from functional disability in the 
year before death of cancer patients in men and 
women by age group.
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Discussion
These data, derived from a nationally representative mor-
tality follow-back survey, provide an empirical confirma-
tion of the validity of these trajectories for patients with
incurable cancers. They confirm the general pattern of the
trajectory and the timing of the onset of functional deteri-
oration, about 3 – 4 months before death. Overall, our
trajectory is very similar to that reported by Teno et al [5]
for cancer patients. Both begin to decline at 6 months
before death. However, the decline in Teno's et al. analysis
is more rapid in the following 2–3 months, whereas our
trajectory suggest that the probability of maintaining
function is high during this period. Our data show a more
rapid decline in the final 3 months of life, which is at
greater variance from the trajectories of cerebrovascular
disease, respiratory failure, congestive heart failure and
diabetes, as suggested by Teno et al [5].
Limitations of this study include the nature of mortality
follow-back surveys, being based on the retrospective
views of lay caregivers, which are subject to recall bias, as
well as representing the caregiver rather than the patient
assessment. However, a review of the validity of this
approach found that for objective, rather than subjective
symptom and psychological, assessments caregiver
reports can be a valid and reliable proxy for patient views
[10]. Although the response rate was high (68%) for this
kind of design, the results may be biased by the effects of
the survey design. As reported in the multivariate analyses
of the baseline data [8] a slightly lower response rate was
observed for patients who died in hospital or nursing
homes compared to home, and when the caregiver was
the spouse. All these patients may have experienced
higher levels of disability, and our results could have
underestimated the total amount of disability. Another
potential source of bias could derive from the different
respondents, as the there were more children and health
professionals respondents for the oldest patients. It may
be that these respondents reported disability in a different
way to spouses. However it is unlikely that this has
affected the overall trajectories.
The main problem with the assessment in this study is
that it considers the major loss of functional ability as a
permanent outcome. Function may fluctuate among can-
cer patients at the end of life. Our interview did not assess
this, but it is questionable whether any retrospective
assessment could do so. Longitudinal prospective studies
would be needed to assess more subtle changes, and to
assess the trajectories of problems such as symptoms and
psychological concerns, all of which might be important
in determining need for palliative care.
Conclusion
Despite its limitations, this study suggests that deteriorat-
ing function is an important prognostic indicator for all
age groups. Co-morbidities probably explain the lower
proportion of older patients with disability one year
before death, but the pattern and starting point (at 12
weeks before death) is consistent across age-groups. Even
among cancer patients over 85 years, a permanent reduc-
tion in function has a high probability to be associated
with commencing the terminal phase of life. This simple
indicator could be used by clinicians to revisit the poten-
tial benefits of aggressive treatments in cancer, initiate dis-
cussion with the patient and caregivers about end of life
Table 2: Probability to be free from functional disability in the year before death of cancer patients by selected characteristics
Probability to be free from functional disability (weeks before death)
N. 52 weeks % 
(95% CI)
24 weeks % 
(95% CI)
18 weeks % 
(95% CI)
12 weeks % 
(95% CI)
6 weeks % 
(95% CI)
4 weeks % 
(95% CI)
2 weeks % 
(95% CI)
Gender
Men 700 95 (93–97) 92 (89–94) 91 (88–93) 68 (63–73) 53 (49–58) 39 (35–44) 27 (23–31)
Women 549 92 (89–94) 88 (84–91) 86 (82–89) 56 (51–62) 43 (37–48) 26 (21–31) 18 (15–22)
Age at death
18–64 242 99 (96–99) 95 (91–97) 93 (89–96) 74 (68–80) 62 (55–68) 43 (36–50) 30 (25–36)
65–84 785 94 (92–96) 92 (89–94) 90 (86–92) 63 (58–68) 47 (43–51) 32 (28–36) 22 (19–25)
85 + 222 85 (79–90) 80 (74–85) 79 (73–84) 50 (42–58) 41 (34–47) 28 (23–33) 19 (14–24)
Primary Tumour
Digestive 453 94 (92–96) 91 (88–94) 90 (87–92) 65 (60–70) 53 (48–58) 35 (30–40) 23 (19–27)
Respiratory 262 97 (93–99) 94 (90–96) 91 (85–95) 69 (61–76) 52 (45–59) 39 (32–46) 28 (23–34)
Breast 124 91 (83–95) 88 (80–93) 87 (80–91) 58 (49–67) 45 (35–55) 24 (15–37) 19 (12–29)
Genitourinary 184 93 (87–97) 87 (80–92) 85 (80–90) 59 (49–68) 41 (33–49) 28 (21–36) 15 (11–23)
Hematological 91 91 (83–95) 90 (82–94) 88 (80–93) 62 (52–72) 52 (42–62) 40 (32–49) 30 (22–40)
Nervous 
Central 
System
32 87 (67–96) 76 (59–87) 72 (56–84) 46 (26–68) 35 (19–55) 14 (5–31) 6 (2–19)
Others 103 92 (84–96) 90 (82–95) 90 (81–95) 60 (44–74) 42 (31–55) 37 (27–49) 28 (18–40)
All patients 1,249 94 (92–95) 90 (88–93) 88 (86–91) 63 (58–68) 49 (45–53) 33 (30–37) 23 (20–26)Publish with BioMed Central    and   every 
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care preferences and referral to palliative care services.
Caregivers and patients could also be given the informa-
tion that functional decline indicates worsening progno-
sis when asking for information about prognosis. Such an
indicator would be useful not only in hospitals, but also
in the community and in nursing and residential homes,
where increasingly older cancer patients are cared for.
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